Adenomyosis

No specific monitoring guidelines have been proposed, and follow-up should be on an individual basis. Initial follow-up after medical or surgical management of adenomyosis is usually performed after 3-6 months to monitor dysmenorrhea and heavy menstrual bleeding symptoms. Follow-up should include monitoring for drug-specific adverse effects, such as mood swings, depression, headaches, gastrointestinal symptoms, breast pain, breakthrough bleeding, or vaginal discharge, which are common with combined oral contraceptives and progestins.

Additionally, vasomotor symptoms and vaginal dryness should be enquired about at follow-up; this is particularly relevant to patients prescribed gonadotropin-releasing hormone (GnRH) agonists, especially before starting add-back therapy.